Targeting HSP90 with Ganetespib to Induce CDK1 Degradation and Promote Cell Death in Hepatoblastoma
HSP90 inhibition by ganetespib demonstrates significant potential as a novel therapeutic strategy for hepatoblastoma, offering a potential alternative to current cytotoxic treatments with fewer adverse effects.
Authors
- Émilie Indersie (ORCID: https://orcid.org/0000-0001-8974-6551)
- Tomoro Hishiki (ORCID: https://orcid.org/0000-0002-2515-1054)
- Eiso Hiyama (ORCID: https://orcid.org/0000-0001-9179-5037)
- Stefano Cairo (ORCID: https://orcid.org/0000-0002-4725-5970)
- Lea Amelie Jung
- Roland Kappler (ORCID: https://orcid.org/0000-0002-8581-2803)
- Alina Hotes
- Salih Demir (ORCID: https://orcid.org/0009-0009-3478-1136)
- Sophie Branchereau
Institutions
- Hiroshima University (JP)
- Chiba University (JP)
- Université Paris-Saclay (FR)
- Assistance Publique – Hôpitaux de Paris (FR)
- Champions Oncology (United States) (US)
- Bicêtre Hospital (FR)
- Ludwig-Maximilians-Universität München (DE)
Publication Details
- Journal
- Cancers
- Published
- 2025-04-16
- DOI
- https://doi.org/10.3390/cancers17081341
- Citations
- 1
- Primary Topic
- Heat shock proteins research
- Type
- article
- Field-Weighted Citation Impact
- 0.81